Prevalence of Hypertension Over (Calendar) Time Among People With Narcolepsy Treated With Oxybate

EPH31

Sarah C. Markt, ScD, MPH[1]; Jennifer Polinski, ScD, MPH, MSc[2]; Marisa Whalen, PharmD[3]; John Kroner, MS[2]; Elizabeth M. Poole, PhD[1]; John Shen, MSPH[2]; Jessica K. Alexander, PhD[1]; Virend K. Somers, MD, PhD[4]

[1]Jazz Pharmaceuticals, Palo Alto, CA, USA; [2]Aetion, Inc., New York, NY, USA; [3]Jazz Pharmaceuticals, Philadelphia, PA, USA; [4]Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

Supplemental Material

- The model for the interrupted time series analysis used the following parameters:

  $E(Y) = \beta_0 + \beta_1 T + \beta_2 X + \beta_3 TX$

  - E(Y) is the average prevalence of hypertension (HTN)
  - β_0 is the prevalence of HTN at the start of the study
  - β_1 is the average change, per month, in the prevalence of HTN pre-introduction to the US market (slope before introduction)
  - T denotes months since the start of the study (ie, 1, 2, 3… n)
  - β_2 is the change in HTN prevalence among SXB initiators between the time point immediately before versus after introduction to the US market (difference in the intercepts of the pre- and post-introduction lines with the Y-axis)
  - X is the binary variable (1,0) that indicates the post-introduction time period (1) versus pre-introduction time period (0)
  - β_3 is the change in trend of HTN prevalence among SXB initiators occurring immediately after the introduction of LXB to the US market (slope post-introduction)